Skip to main content

Biotechnology Value Fund L P's Form 4 filing

Repare Therapeutics Inc. (RPTX) · filed May 20, 2022

Accession no.
0000921895-22-001756
Filed
May 20, 2022, 6:09 PM ET
Trade date
May 18, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $3.57M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 0000918923Other: See Explanation of Responses
BVF Partners L PCIK 000105594710% Owner
BVF IncCIK 000105680710% Owner
Biotechnology Value Fund II LPCIK 0001102444Other: See Explanation of Responses
Lampert Mark NCIK 000123384010% Owner
Biotechnology Value Trading Fund OS LPCIK 0001660683Other: See Explanation of Responses
BVF Partners OS Ltd.CIK 0001660684Other: See Explanation of Responses
BVF I GP LLCCIK 0001803805Other: See Explanation of Responses
BVF II GP LLCCIK 0001803806Other: See Explanation of Responses
BVF GP Holdings LLCCIK 000180380910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 18, 2022Common Shares, no par valuePPurchaseAcquired+224,388$8.50+$1,907,2983,350,950Direct
May 18, 2022Common Shares, no par valuePPurchaseAcquired+189,882$8.50+$1,613,9972,505,507Direct
May 18, 2022Common Shares, no par valuePPurchaseAcquired+5,730$8.50+$48,705313,357Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)